,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11110964,2913,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11110965,2913,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,410,1,5,,11110964,2913,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
3,410,1,5,,11110965,2913,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,410,1,5,,11113362,2913,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
5,411,2,1,,11110964,2913,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
6,411,2,1,,11110965,2913,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
7,411,2,1,,11113362,2913,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
8,444,1,1,,11110964,2913,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
9,444,1,1,,11110965,2913,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
10,445,3,1,,11110964,2913,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
11,445,3,1,,11110965,2913,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
12,445,3,1,,11113362,2913,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
13,446,1,1,,11110964,2913,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
14,446,1,1,,11110965,2913,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
15,447,1,1,,11110964,2913,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
16,447,1,1,,11110965,2913,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
17,447,1,1,,11113362,2913,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
18,448,1,2,,11110964,2913,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
19,448,1,2,,11110965,2913,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
20,448,1,2,,11113362,2913,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
21,450,1,2,,11110964,2913,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
22,450,1,2,,11110965,2913,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
23,450,1,2,,11113362,2913,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
24,451,1,2,,11110964,2913,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
25,451,1,2,,11110965,2913,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
26,451,1,2,,11113362,2913,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
27,526,1,1,,11110964,2913,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
28,526,1,1,,11110965,2913,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
29,526,1,1,,11113362,2913,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
30,530,1,1,,11110964,2913,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
31,530,1,1,,11110965,2913,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
32,530,1,1,,11113362,2913,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
33,584,1,3,,11110964,2913,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
34,584,1,3,,11110965,2913,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
35,584,1,3,,11113362,2913,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
36,585,1,4,,11110964,2913,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
37,585,1,4,,11110965,2913,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
38,585,1,4,,11113362,2913,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
39,587,1,5,,11110964,2913,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
40,587,1,5,,11110965,2913,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
41,588,1,4,,11110964,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
42,588,1,4,,11110965,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
43,589,1,3,,11110964,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
44,589,1,3,,11110965,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
45,590,1,3,,11110964,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
46,590,1,3,,11110965,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
47,591,1,4,,11110964,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
48,591,1,4,,11110965,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
49,592,1,6,,11110964,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
50,592,1,6,,11110965,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
51,593,1,4,,11110964,2913,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
52,593,1,4,,11110965,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
53,594,1,4,,11110964,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
54,594,1,4,,11110965,2913,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
55,595,1,3,,11110964,2913,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
56,595,1,3,,11110965,2913,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
57,595,1,3,,11113362,2913,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
58,596,1,2,,11110964,2913,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
59,596,1,2,,11110965,2913,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
60,596,1,2,,11113362,2913,Inconclusive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
61,597,1,3,,11110964,2913,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
62,597,1,3,,11110965,2913,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
63,597,1,3,,11113362,2913,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
64,603,1,2,,11110964,2913,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
65,603,1,2,,11110965,2913,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
66,603,1,2,,11113362,2913,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
67,605,1,2,,11110964,2913,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
68,605,1,2,,11110965,2913,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
69,605,1,2,,11113362,2913,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
70,607,1,3,,11110964,2913,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
71,607,1,3,,11110965,2913,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
72,607,1,3,,11113362,2913,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
73,662,1,1,,11110964,2913,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
74,662,1,1,,11110965,2913,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
75,662,1,1,,11113362,2913,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
76,875,1,2,,11110964,2913,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
77,875,1,2,,11110965,2913,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
78,875,1,2,,11113362,2913,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
79,879,1,2,,11110964,2913,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
80,879,1,2,,11110964,2913,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
81,880,2,1,,11110965,2913,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
82,880,2,1,,11110965,2913,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
83,880,2,1,,11113362,2913,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
84,880,2,1,,11113362,2913,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
85,880,2,1,,26751603,2913,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
86,880,2,1,,26751603,2913,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
87,881,2,2,,11110964,2913,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
88,881,2,2,,11110965,2913,Inactive,317373425.0,247.0,10.0,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
89,881,2,2,,11113362,2913,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
90,883,1,3,,11110964,2913,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
91,883,1,3,,11110965,2913,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
92,883,1,3,,11113362,2913,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
93,884,1,2,,11110964,2913,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
94,884,1,2,,11110965,2913,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
95,884,1,2,,11113362,2913,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
96,885,1,2,,11110964,2913,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
97,885,1,2,,11110965,2913,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
98,885,1,2,,11113362,2913,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
99,886,1,2,,11110964,2913,Inconclusive,122921310.0,,19.9526,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
100,886,1,2,,11110964,2913,Inconclusive,122921311.0,,19.9526,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
101,886,1,2,,11110965,2913,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
102,886,1,2,,11110965,2913,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
103,886,1,2,,11113362,2913,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
104,886,1,2,,11113362,2913,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
105,887,1,2,,11110964,2913,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
106,887,1,2,,11110965,2913,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
107,887,1,2,,11113362,2913,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
108,889,1,3,,11110964,2913,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
109,889,1,3,,11110965,2913,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
110,889,1,3,,11113362,2913,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
111,891,1,2,,11110964,2913,Active,40805836.0,1565.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
112,891,1,2,,11110965,2913,Active,40805836.0,1565.0,2.5119,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
113,891,1,2,,11113362,2913,Active,40805836.0,1565.0,3.9811,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
114,892,1,2,,11110964,2913,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
115,892,1,2,,11110965,2913,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
116,892,1,2,,11113362,2913,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
117,893,1,2,,11110964,2913,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
118,893,1,2,,11110964,2913,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
119,893,1,2,,11110965,2913,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
120,893,1,2,,11110965,2913,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
121,893,1,2,,11113362,2913,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
122,893,1,2,,11113362,2913,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
123,894,2,1,,11110965,2913,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
124,894,2,1,,11113362,2913,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
125,895,1,2,,11110964,2913,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
126,899,1,2,,11110964,2913,Inconclusive,4503219.0,1557.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
127,899,1,2,,11110965,2913,Inconclusive,4503219.0,1557.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
128,899,1,2,,11113362,2913,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
129,900,1,3,,11110964,2913,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
130,900,1,3,,11110965,2913,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
131,900,1,3,,11113362,2913,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
132,901,1,2,,11110964,2913,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
133,901,1,2,,11110965,2913,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
134,901,1,2,,11113362,2913,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
135,902,1,2,,11110964,2913,Inconclusive,120407068.0,7157.0,12.5893,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
136,902,1,2,,11110965,2913,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
137,902,1,2,,11113362,2913,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
138,912,1,2,,11110964,2913,Inconclusive,21392848.0,,3.9811,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
139,912,1,2,,11110965,2913,Active,21392848.0,,7.9433,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
140,912,1,2,,11113362,2913,Inconclusive,21392848.0,,12.5893,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
141,914,1,3,,11110964,2913,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
142,914,1,3,,11110965,2913,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
143,915,1,3,,11110964,2913,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
144,915,1,3,,11110965,2913,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
145,917,1,3,,11110964,2913,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
146,918,1,3,,11110964,2913,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
147,923,1,2,,11110964,2913,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
148,923,1,2,,11110965,2913,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
149,923,1,2,,11113362,2913,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
150,924,1,2,,11110964,2913,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
151,924,1,2,,11110965,2913,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
152,924,1,2,,11113362,2913,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
153,925,1,2,,11110964,2913,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
154,925,1,2,,11110965,2913,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
155,926,1,2,,11110964,2913,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
156,926,1,2,,11110965,2913,Unspecified,38016895.0,7253.0,1.0,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
157,926,1,2,,11113362,2913,Inconclusive,38016895.0,7253.0,10.0,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
158,927,1,3,,11110964,2913,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
159,927,1,3,,11110965,2913,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
160,928,1,2,,11110964,2913,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
161,938,1,2,,11110964,2913,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
162,938,1,2,,11110965,2913,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
163,938,1,2,,11113362,2913,Inconclusive,38016895.0,7253.0,10.0,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
164,943,1,2,,11110964,2913,Active,18249941.0,25229.0,0.0224,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
165,944,1,2,,11110964,2913,Active,18249941.0,25229.0,0.0316,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
166,945,1,4,,11110964,2913,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
167,954,1,2,,11110964,2913,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
168,957,1,2,,11110964,2913,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
169,958,1,2,,11110964,2913,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
170,959,1,4,,11110964,2913,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
171,992,1,3,,11110964,2913,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
172,995,1,2,,11110964,2913,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
173,995,1,2,,11110965,2913,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
174,995,1,2,,11113362,2913,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
175,997,1,2,,11110964,2913,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
176,998,1,2,,11110964,2913,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
177,1030,2,1,,11110965,2913,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
178,1030,2,1,,11113362,2913,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
179,1030,2,1,,26751603,2913,Inconclusive,30582681.0,216.0,37.6505,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
180,1195,1,2,,48415832,2913,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
181,1332,1,1,,49698345,2913,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
182,1379,1,2,,11110965,2913,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
183,1379,1,2,,11113362,2913,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
184,1452,1,1,,11110964,2913,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
185,1452,1,1,,11110965,2913,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
186,1452,1,1,,11113362,2913,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
187,1454,1,1,,11110965,2913,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
188,1454,1,1,,11113362,2913,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
189,1457,1,1,,11110965,2913,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
190,1457,1,1,,11113362,2913,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
191,1457,1,1,,26751603,2913,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
192,1458,1,1,,11110965,2913,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
193,1458,1,1,,26751603,2913,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
194,1460,1,3,,11113362,2913,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
195,1460,1,3,,26751603,2913,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
196,1463,1,1,,11113362,2913,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
197,1463,1,1,,26751603,2913,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
198,1467,1,3,,11110965,2913,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
199,1467,1,3,,11113362,2913,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
200,1468,1,1,,11113362,2913,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
201,1468,1,1,,26751603,2913,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
202,1469,1,1,,11110965,2913,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
203,1469,1,1,,11113362,2913,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
204,1469,1,1,,26751603,2913,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
205,1471,2,1,,11110964,2913,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
206,1471,2,1,,11110965,2913,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
207,1471,2,1,,11113362,2913,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
208,1471,2,1,,26751603,2913,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
209,1476,2,1,,11110965,2913,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
210,1476,2,1,,11113362,2913,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
211,1477,1,1,,11110965,2913,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
212,1477,1,1,,11113362,2913,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
213,1477,1,1,,26751603,2913,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
214,1478,2,1,,11110965,2913,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
215,1478,2,1,,11113362,2913,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
216,1479,1,2,,11110965,2913,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
217,1479,1,2,,11113362,2913,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
218,1479,1,2,,26751603,2913,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
219,1487,1,1,,11110965,2913,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
220,1487,1,1,,26751603,2913,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
221,1490,2,1,,11110965,2913,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
222,1490,2,1,,11113362,2913,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
223,1490,2,1,,26751603,2913,Active,10954339.0,,44.6684,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
224,1519,1,3,,11110965,2913,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
225,1519,1,3,,11113362,2913,Inconclusive,,,3.1623,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
226,1688,1,1,,26751603,2913,Inconclusive,90903231.0,3064.0,35.4813,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
227,1766,1,1,,11110965,2913,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
228,1766,1,1,,11110965,2913,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
229,1766,1,1,,11113362,2913,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
230,1766,1,1,,11113362,2913,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
231,1766,1,1,,26751603,2913,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
232,1766,1,1,,26751603,2913,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
233,1768,1,1,,11110965,2913,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
234,1768,1,1,,11110965,2913,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
235,1768,1,1,,11113362,2913,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
236,1768,1,1,,11113362,2913,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
237,1768,1,1,,26751603,2913,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
238,1768,1,1,,26751603,2913,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
239,1851,1,2,,11110964,2913,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
240,1851,1,2,,11110965,2913,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
241,1851,1,2,,11113362,2913,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
242,1851,1,2,1.0,11110964,2913,Inconclusive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
243,1851,1,2,1.0,11110965,2913,Inconclusive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
244,1851,1,2,1.0,11113362,2913,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
245,1851,1,2,2.0,11110964,2913,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
246,1851,1,2,2.0,11110965,2913,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
247,1851,1,2,2.0,11113362,2913,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
248,1851,1,2,3.0,11110964,2913,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
249,1851,1,2,3.0,11110965,2913,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
250,1851,1,2,3.0,11113362,2913,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
251,1851,1,2,4.0,11110964,2913,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
252,1851,1,2,4.0,11110965,2913,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
253,1851,1,2,4.0,11113362,2913,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
254,1851,1,2,5.0,11110964,2913,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
255,1851,1,2,5.0,11110965,2913,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
256,1851,1,2,5.0,11113362,2913,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
257,1865,1,1,,11110965,2913,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
258,1865,1,1,,11113362,2913,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
259,1865,1,1,,26751603,2913,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
260,1948,1,1,,11110965,2913,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
261,1948,1,1,,11113362,2913,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
262,2062,1,2,,85209714,2913,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
263,2101,1,1,,11110965,2913,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
264,2101,1,1,,11113362,2913,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
265,2101,1,1,,26751603,2913,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
266,2107,1,1,,11110965,2913,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
267,2107,1,1,,11113362,2913,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
268,2107,1,1,,26751603,2913,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
269,2112,1,1,,11110965,2913,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
270,2112,1,1,,11113362,2913,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
271,2112,1,1,,26751603,2913,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
272,2147,1,1,,11110965,2913,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
273,2147,1,1,,11113362,2913,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
274,2240,1,1,,85787813,2913,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
275,2240,1,1,,85788782,2913,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
276,2241,1,1,,85787813,2913,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
277,2241,1,1,,85788782,2913,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
278,2275,1,1,,85787813,2913,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
279,2275,1,1,,85788782,2913,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
280,2313,1,1,,85787813,2913,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
281,2313,1,1,,85788782,2913,Inconclusive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
282,2316,1,1,,85787813,2913,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
283,2322,1,1,,85787813,2913,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
284,2322,1,1,,85788782,2913,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
285,2330,1,1,,85787813,2913,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
286,2330,1,1,,85788782,2913,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
287,2451,1,2,,11110965,2913,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
288,2451,1,2,,11113362,2913,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
289,2472,1,2,,11110965,2913,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
290,2472,1,2,,11113362,2913,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
291,2517,2,1,,11110965,2913,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
292,2517,2,1,,11113362,2913,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
293,2517,2,1,,26751603,2913,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
294,2528,1,2,,11110965,2913,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
295,2528,1,2,,11113362,2913,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
296,2528,1,2,,26751603,2913,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
297,2546,1,1,,11110965,2913,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
298,2546,1,1,,11113362,2913,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
299,2546,1,1,,26751603,2913,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
300,2549,1,1,,11110965,2913,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
301,2549,1,1,,11113362,2913,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
302,2549,1,1,,26751603,2913,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
303,2551,1,1,,11110965,2913,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
304,2551,1,1,,11113362,2913,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
305,2551,1,1,,26751603,2913,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
306,2660,1,1,,90341656,2913,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
307,2666,1,1,,90341656,2913,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
308,2667,1,1,,90341656,2913,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
309,2668,1,1,,90341656,2913,Inconclusive,4826730.0,2475.0,26.1216,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
310,2701,1,1,,26751603,2913,Active,10954339.0,,83.4814,Potency,Confirmation qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
311,2707,1,2,,26751603,2913,Inactive,10954339.0,,,Potency,Gel-Based Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
312,4791,7,2,,103173872,2913,Active,,,0.0031,IC50,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Confirmatory,8151622.0,
313,5355,7,2,,103173872,2913,Active,,,0.003,Ki,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Confirmatory,15081025.0,
314,5444,7,1,,103173872,2913,Active,,,0.0016,Ki,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Confirmatory,11266163.0,
315,5514,7,1,,103173872,2913,Active,,,0.0016,Ki,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,Confirmatory,11229772.0,
316,5572,8,5,,103173872,2913,Active,112808.0,29595.0,0.005,Ki,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Confirmatory,,
317,5677,9,1,,103173872,2913,Active,,,0.011000000000000001,Ki,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
318,5945,7,2,,103173872,2913,Active,,,0.011000000000000001,Ki,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Confirmatory,15081025.0,
319,6426,9,2,,103173872,2913,Active,112808.0,29595.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
320,6426,9,2,,103173872,2913,Active,112812.0,24473.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
321,6426,9,2,,103173872,2913,Active,112815.0,25075.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
322,6426,9,2,,103173872,2913,Active,112817.0,25187.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
323,6426,9,2,,103173872,2913,Active,112820.0,25323.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
324,6426,9,2,,103173872,2913,Active,398968.0,60448.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
325,6426,9,2,,103173872,2913,Active,398970.0,29581.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
326,6426,9,2,,103173872,2913,Active,461440.0,65032.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
327,6426,9,2,,103173872,2913,Active,543729.0,25689.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
328,6426,9,2,,103173872,2913,Active,543730.0,79247.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
329,6426,9,2,,103173872,2913,Active,1168221.0,64354.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
330,6426,9,2,,103173872,2913,Active,1168223.0,79246.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
331,6426,9,2,,103173872,2913,Active,2494928.0,25324.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
332,6426,9,2,,103173872,2913,Active,81868595.0,58963.0,0.007940000000000001,Kd,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Confirmatory,,
333,6670,6,2,,103173872,2913,Active,,,0.05012,Ki,Binding affinity towards 5-hydroxytryptamine 7 receptor,Confirmatory,10843226.0,
334,6685,4,1,,103173872,2913,Active,,,0.05012,Ki,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,Confirmatory,14667218.0,
335,23960,3,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
336,23962,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
337,23964,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
338,23966,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
339,23968,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
340,23970,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
341,23972,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
342,23973,4,3,,103173872,2913,Unspecified,,,,,"Partition coefficient (logD, measured by HPLC, log k')",Other,6167716.0,
343,23975,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
344,23976,4,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
345,26296,4,4,,103173872,2913,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
346,26310,4,4,,103173872,2913,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
347,26311,3,3,,103173872,2913,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
348,49213,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 46/193,Other,7069703.0,
349,49217,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 35/118,Other,7069703.0,
350,49221,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 41/160,Other,7069703.0,
351,49237,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 59/195,Other,7069703.0,
352,49240,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 14/112,Other,7069703.0,
353,49246,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 28/130,Other,7069703.0,
354,49386,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 45/231,Other,7069703.0,
355,49394,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 34/165,Other,7069703.0,
356,49401,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 35/200,Other,7069703.0,
357,49413,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 50/256,Other,7069703.0,
358,49421,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 47/190,Other,7069703.0,
359,49570,3,3,,103173872,2913,Unspecified,,,,,Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 50/221,Other,7069703.0,
360,58617,3,5,,103173872,2913,Unspecified,,,,,Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing 50% reduction in ectopic rate..,Other,7452678.0,
361,58619,3,5,,103173872,2913,Unspecified,,,,,Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing for conversion to sinus rhythm.,Other,7452678.0,
362,61054,7,1,,103173872,2913,Active,,,0.11199999999999999,Ki,Binding affinity to Dopamine receptor D2 using [3H]spiperone as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
363,61545,7,2,,103173872,2913,Active,,,0.14,IC50,Binding affinity at dopamine D2 receptor by [3H]spiperone displacement.,Confirmatory,8151622.0,
364,63015,7,2,,103173872,2913,Active,,,0.063,Ki,Displacement of [3H]- spiperone radioligand binding at the dopamine binding site of rat caudate,Confirmatory,6134835.0,
365,63979,7,2,,103173872,2913,Active,,,0.11199999999999999,Ki,Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand,Confirmatory,15081025.0,
366,76788,6,2,,103173872,2913,Unspecified,,,,,In vivo histamine induced lethality after 24 hours of iv administration in guinea pig,Other,3934386.0,
367,76789,6,2,,103173872,2913,Unspecified,,,,,In vivo histamine induced lethality after 3 hours of iv administration in guinea pig,Other,3934386.0,
368,76791,6,2,,103173872,2913,Unspecified,,,,,In vivo histamine induced lethality after 8 hours of iv administration in guinea pig,Other,3934386.0,
369,86241,8,5,,103173872,2913,Active,399889.0,100730517.0,0.001,Kd,Potency against histamine H1 receptor on guinea pig ileum,Confirmatory,7650688.0,
370,86244,4,1,,103173872,2913,Active,399889.0,100730517.0,0.000537,Ki,Inhibition of [3H]mepyramine binding with histamine H1 receptor in guinea pig cerebellum membranes after 30 min,Confirmatory,7650688.0,
371,112444,5,3,,103173872,2913,Unspecified,,,,,"Inhibitory dose against (+/-)DOI induced (2.5 mg/kg, ip) head twitch response in mice",Other,,
372,127990,6,2,,103173872,2913,Unspecified,,,,,5 HTP (5-hydroxytryptophan) antagonism in mouse 0.5 hr after subcutaneous administration (0.003-0.1 dose range).,Other,6600791.0,
373,141115,7,1,,103173872,2913,Active,,,0.004,Ki,Displacement of [3H]- QNB binding at the muscarinic-cholinergic binding site of rat brain S1,Confirmatory,6134835.0,
374,145696,7,1,,103173872,2913,Active,,,0.29,Ki,Binding affinity to Norepinephrine transporter using [3H]-nisoxatine as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
375,145895,7,2,,103173872,2913,Active,,,0.29,Ki,Binding affinity towards Norepinephrine transporter using [3H]nisoxitine as radioligand,Confirmatory,15081025.0,
376,170073,2,4,,103173872,2913,Unspecified,,,,,Percent activity for blocking of discriminative property stimulated by (+/-) DOI in rats at 1 mg/kg(+/-DOI 0.35 mg/kg administered to animals pretreated with compound),Other,,
377,176160,6,2,,103173872,2913,Unspecified,,,,,In vivo antihistaminic activity using compound 48/80 induced lethality test in rat after 2 hr( oral administration),Other,3934386.0,
378,178522,6,2,,103173872,2913,Unspecified,,,,,Inhibition of histamine skin reaction in rat after 2 hr of oral administration.,Other,3934386.0,
379,178529,6,2,,103173872,2913,Unspecified,,,,,Inhibition of mydriatic activity in rat after 2 hr of oral administration.,Other,3934386.0,
380,178534,6,2,,103173872,2913,Unspecified,,,,,Inhibition of serotonin skin reaction in rat after 2 hr of oral administration.,Other,3934386.0,
381,187343,2,6,,103173872,2913,Active,,,,,"Number of responding rats/number of rats to receive the compound at a dose of 1 mg/kg, +/-DOI 0.35 mg/kg was administered intraperitoneally 60 min before test; 9/9",Other,,
382,190718,2,4,,103173872,2913,Unspecified,,,,,"Blocking of discriminative property stimulated by DOI in rats at 1 mg/kg dose, activity expressed as response/min(+/-DOI 0.35 mg/kg administered to animals pretreated with compound)",Other,,
383,203926,6,4,,103173872,2913,Unspecified,,,,,Serotonin antagonism in guinea pig 3 h after oral administration.,Other,6600791.0,
384,203927,7,4,,103173872,2913,Unspecified,,,,,Serotonin antagonism in guinea pig 3 hr after subcutaneous administration.,Other,6600791.0,
385,204217,7,2,,103173872,2913,Active,,,4.1,Ki,Binding affinity to Serotonin transporter using [3H]-paroxetine as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
386,204880,7,3,,103173872,2913,Active,,,4.1,Ki,Binding affinity towards Serotonin transporter using [3H]paroxetine as radioligand,Confirmatory,15081025.0,
387,205267,9,2,,103173872,2913,Active,,,1.0,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
388,205268,4,7,,103173872,2913,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
389,214939,7,3,,103173872,2913,Unspecified,,,150.0,Km,Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4),Confirmatory,12699380.0,
390,227718,7,1,,103173872,2913,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
391,254254,10,5,,103173872,2913,Active,547645.0,3269.0,5.4,Kd,Dissociation constant against histamine H1 receptor,Confirmatory,16220969.0,
392,254947,10,5,,103173872,2913,Unspecified,123779610.0,100135514.0,100.0,IC50,Inhibitory concentration against LTD4-induced contraction of guinea pig ileum at 10 uM concentration,Confirmatory,16220969.0,
393,311932,3,10,,103173872,2913,Unspecified,224471897.0,6609.0,,,Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM,Other,18027916.0,
394,311934,3,3,,103173872,2913,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
395,311935,3,4,,103173872,2913,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
396,330659,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 50 uM,Other,18033297.0,
397,330660,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 100 uM,Other,18033297.0,
398,330691,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans N2 treated on day 1 at 50 uM,Other,18033297.0,
399,330692,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of diet restricted Caenorhabditis elegans N2 at 50 uM,Other,18033297.0,
400,330696,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans daf16(mu86) mutant at 50 uM,Other,18033297.0,
401,330698,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans eat2(ad1116) mutant at 50 uM,Other,18033297.0,
402,330703,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans ser3(ok2007) mutant at 50 uM,Other,18033297.0,
403,330704,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans ser4(ok512) mutant at 50 uM,Other,18033297.0,
404,330705,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans ser7(tm1325) mutant at 50 uM,Other,18033297.0,
405,330724,3,3,,103173872,2913,Unspecified,,,,,Effect on life span of Caenorhabditis elegans N2 treated on day 5 at 50 uM,Other,18033297.0,
406,337405,3,4,,103173872,2913,Unspecified,,,,,"Antiinflammatory activity against PLA2-induced Swiss mouse paw edema at 5 mg/kg, ip administered 30 mins before PLA2 challenge",Other,14510620.0,
407,337406,3,4,,103173872,2913,Unspecified,,,,,"Antiinflammatory activity against PLA2-induced Swiss mouse paw edema at 5 mg/kg, ip administered 60 mins before PLA2 challenge",Other,14510620.0,
408,356052,3,3,,103173872,2913,Unspecified,,,,,"Antiinflammatory activity against Naja mossambica PLA2-induced Swiss mouse paw edema assessed as inhibition of paw volume at 5 mg/kg, ip administered before 30 mins of PLA2 challenge measured after 30 mins relative to control",Other,12828487.0,
409,356053,3,3,,103173872,2913,Unspecified,,,,,"Antiinflammatory activity against Naja mossambica PLA2-induced Swiss mouse paw edema assessed as inhibition of paw volume at 5 mg/kg, ip administered before 30 mins of PLA2 challenge measured after 60 mins relative to control",Other,12828487.0,
410,434959,1,1,,85787813,2913,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
411,434959,1,1,,85788782,2913,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
412,463106,1,2,,90341656,2913,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
413,485281,1,1,,11110965,2913,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
414,485290,1,1,,11110965,2913,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
415,485290,1,1,,11113362,2913,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
416,485290,1,1,,26751603,2913,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
417,485295,1,2,,90341656,2913,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
418,485297,1,1,,90341656,2913,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
419,485298,1,1,,90341656,2913,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
420,485313,1,2,,90341656,2913,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
421,485342,1,2,,90341656,2913,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
422,485345,1,2,,90341656,2913,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
423,485366,1,2,,90341656,2913,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
424,485368,1,2,,90341656,2913,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
425,488772,1,1,,90341656,2913,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
426,488773,1,2,,90341656,2913,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
427,488816,1,1,,90341656,2913,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
428,488837,1,1,,90341656,2913,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
429,488949,1,2,,90341656,2913,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
430,488953,1,1,,90341656,2913,Inconclusive,187960037.0,10951.0,44.6684,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
431,488978,1,1,,90341656,2913,Inconclusive,45359078.0,,100.0,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
432,488981,1,1,,90341656,2913,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
433,488982,1,1,,90341656,2913,Inactive,4503383.0,1812.0,0.4109,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
434,488983,1,1,,90341656,2913,Active,4503383.0,1812.0,1.9953,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
435,493106,1,1,,90341656,2913,Inactive,116283940.0,79915.0,23.0999,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
436,493107,1,1,,90341656,2913,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
437,493153,1,1,,90341656,2913,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
438,493153,1,1,,90341656,2913,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
439,493164,1,2,,90341656,2913,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
440,493164,1,2,,90341656,2913,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
441,493164,1,2,,90341656,2913,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
442,504327,1,1,,11110965,2913,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
443,504327,1,1,,90341656,2913,Inconclusive,153791535.0,2648.0,39.8107,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
444,504332,1,1,,11110965,2913,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
445,504332,1,1,,90341656,2913,Inconclusive,168985070.0,,37.6858,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
446,504536,1,1,,90341656,2913,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
447,504547,1,1,,90341656,2913,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
448,504548,1,2,,90341656,2913,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
449,504749,1,3,,26751603,2913,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
450,504749,1,3,,104171133,2913,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
451,504749,1,3,1.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
452,504749,1,3,2.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
453,504749,1,3,3.0,104171133,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
454,504749,1,3,4.0,26751603,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
455,504749,1,3,5.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
456,504749,1,3,6.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
457,504749,1,3,7.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
458,504749,1,3,8.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
459,504749,1,3,9.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
460,504749,1,3,10.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
461,504749,1,3,11.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
462,504749,1,3,12.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
463,504749,1,3,13.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
464,504749,1,3,14.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
465,504749,1,3,15.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
466,504749,1,3,16.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
467,504749,1,3,17.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
468,504749,1,3,18.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
469,504749,1,3,19.0,26751603,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
470,504749,1,3,20.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
471,504749,1,3,21.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
472,504749,1,3,22.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
473,504749,1,3,23.0,104171133,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
474,504749,1,3,24.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
475,504749,1,3,25.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
476,504749,1,3,26.0,26751603,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
477,504749,1,3,27.0,104171133,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
478,504749,1,3,28.0,104171133,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
479,504749,1,3,29.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
480,504749,1,3,30.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
481,504749,1,3,31.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
482,504749,1,3,32.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
483,504749,1,3,33.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
484,504749,1,3,34.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
485,504749,1,3,35.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
486,504749,1,3,36.0,104171133,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
487,504749,1,3,37.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
488,504749,1,3,38.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
489,504749,1,3,39.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
490,504749,1,3,40.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
491,504749,1,3,41.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
492,504749,1,3,42.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
493,504749,1,3,43.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
494,504749,1,3,44.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
495,504749,1,3,45.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
496,504749,1,3,46.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
497,504749,1,3,47.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
498,504749,1,3,48.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
499,504749,1,3,49.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
500,504749,1,3,50.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
501,504749,1,3,51.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
502,504749,1,3,52.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
503,504749,1,3,53.0,104171133,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
504,504749,1,3,54.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
505,504749,1,3,55.0,104171133,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
506,504749,1,3,56.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
507,504749,1,3,57.0,26751603,2913,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
508,504749,1,3,58.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
509,504749,1,3,59.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
510,504749,1,3,60.0,104171133,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
511,504749,1,3,61.0,26751603,2913,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
512,504810,1,2,,90341656,2913,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
513,504812,1,2,,90341656,2913,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
514,504832,1,1,,104171133,2913,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
515,504834,1,1,,104171133,2913,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
516,504836,1,2,,90341656,2913,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
517,504845,1,1,,90341656,2913,Inconclusive,86301163.0,5999.0,2.6654,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
518,504845,1,1,,104171133,2913,Inconclusive,86301163.0,5999.0,4.7444,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
519,504847,1,1,,11110965,2913,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
520,504847,1,1,,90341656,2913,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
521,504847,1,1,,104171133,2913,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
522,504865,1,1,,11110965,2913,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
523,504865,1,1,,90341656,2913,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
524,504865,1,1,,104171133,2913,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
525,540256,1,2,,90341656,2913,Active,,,8.1961,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
526,540276,1,2,,11110964,2913,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
527,540276,1,2,,11110965,2913,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
528,540276,1,2,,11113362,2913,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
529,540276,1,2,,26751603,2913,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
530,540276,1,2,,50100203,2913,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
531,540276,1,2,,50104260,2913,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
532,540276,1,2,,90341656,2913,Inconclusive,420597.0,,12.99,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
533,588211,2,3,,103173872,2913,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
534,588212,2,3,,103173872,2913,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
535,588213,2,3,,103173872,2913,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
536,588349,1,1,,90341656,2913,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
537,588378,1,1,,90341656,2913,Inconclusive,171543895.0,6311.0,19.9526,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
538,588379,1,2,,124879679,2913,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
539,588453,1,1,,90341656,2913,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
540,588456,1,1,,90341656,2913,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
541,588579,1,1,,11110965,2913,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
542,588579,1,1,,90341656,2913,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
543,588579,1,1,,104171133,2913,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
544,588579,1,1,,124879679,2913,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
545,588795,1,1,,90341656,2913,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
546,588834,2,1,,26751603,2913,Inconclusive,325651834.0,3757.0,11.2202,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
547,602332,1,1,,11110965,2913,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
548,602332,1,1,,90341656,2913,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
549,602332,1,1,,104171133,2913,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
550,602332,1,1,,124879679,2913,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
551,624030,1,2,,104171133,2913,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
552,624031,1,2,,104171133,2913,Inconclusive,,,8.0875,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
553,624032,1,2,,104171133,2913,Inconclusive,8393992.0,24660.0,12.8178,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
554,624044,1,2,,104171133,2913,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
555,624137,1,1,,85787813,2913,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
556,624146,1,1,,90341656,2913,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
557,624147,1,1,,90341656,2913,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
558,624148,1,2,,90341656,2913,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
559,624149,1,1,,90341656,2913,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
560,624156,1,1,,85787813,2913,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
561,624156,1,1,,85788782,2913,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
562,624170,1,1,,104171133,2913,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
563,624172,1,1,,104171133,2913,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
564,624173,1,3,,104171133,2913,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
565,624180,1,1,,135650152,2913,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8394362.0,
566,624180,1,1,,135650152,2913,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8397408.0,
567,624181,1,1,,135650152,2913,Active,10880131.0,3363.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT7,Other,8226867.0,
568,624190,1,1,,135650152,2913,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,7680751.0,
569,624192,1,1,,135650152,2913,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,8522988.0,
570,624260,1,1,,85787813,2913,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
571,624296,1,1,,26751603,2913,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
572,624296,1,1,,104171133,2913,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
573,624297,1,1,,26751603,2913,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
574,624297,1,1,,104171133,2913,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
575,624349,1,2,,92309316,2913,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
576,624455,1,1,,90341656,2913,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
577,624606,1,9,,103173872,2913,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
578,624607,1,9,,103173872,2913,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
579,624608,3,2,,103173872,2913,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
580,624609,1,9,,103173872,2913,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
581,624612,1,9,,103173872,2913,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
582,624616,1,8,,103173872,2913,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
583,624632,3,7,,103173872,2913,Unspecified,549152.0,54659.0,240.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A3,Confirmatory,15781124.0,
584,624633,3,7,,103173872,2913,Unspecified,136731.0,54657.0,62.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A4,Confirmatory,15781124.0,
585,625144,5,5,,103173872,2913,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
586,625145,4,7,,103173872,2913,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
587,625146,5,5,,103173872,2913,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
588,625147,4,7,,103173872,2913,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
589,625148,4,7,,103173872,2913,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
590,625149,4,7,,103173872,2913,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
591,625150,5,5,,103173872,2913,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
592,625151,4,7,,103173872,2913,Active,113118.0,1128.0,0.016,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
593,625152,4,7,,103173872,2913,Active,113122.0,1129.0,0.035,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
594,625153,4,7,,103173872,2913,Active,113125.0,1131.0,0.046,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
595,625154,4,7,,103173872,2913,Active,23503039.0,1132.0,0.016,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
596,625155,4,7,,103173872,2913,Active,543761.0,1133.0,0.0038399999999999997,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
597,625156,1,9,,103173872,2913,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
598,625157,6,2,,103173872,2913,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
599,625158,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
600,625159,5,5,,103173872,2913,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
601,625160,1,9,,103173872,2913,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
602,625161,4,7,,103173872,2913,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
603,625162,4,7,,103173872,2913,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
604,625163,4,7,,103173872,2913,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
605,625164,1,6,,103173872,2913,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
606,625165,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
607,625166,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
608,625167,5,5,,103173872,2913,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
609,625168,4,7,,103173872,2913,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
610,625169,1,6,,103173872,2913,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
611,625170,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
612,625171,4,7,,103173872,2913,Active,7531135.0,3757.0,17.0491,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
613,625172,4,7,,103173872,2913,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
614,625173,5,5,,103173872,2913,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
615,625174,5,5,,103173872,2913,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
616,625175,5,5,,103173872,2913,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
617,625176,1,9,,103173872,2913,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
618,625177,5,5,,103173872,2913,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
619,625178,5,5,,103173872,2913,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
620,625179,1,9,,103173872,2913,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
621,625180,5,5,,103173872,2913,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
622,625181,5,5,,103173872,2913,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
623,625182,5,5,,103173872,2913,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
624,625183,5,5,,103173872,2913,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
625,625184,5,5,,103173872,2913,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
626,625185,5,5,,103173872,2913,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
627,625186,5,5,,103173872,2913,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
628,625187,5,5,,103173872,2913,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
629,625188,1,9,,103173872,2913,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
630,625189,1,7,,103173872,2913,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
631,625190,4,5,,103173872,2913,Active,,,0.122,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
632,625191,4,7,,103173872,2913,Active,112815.0,25075.0,2.778,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
633,625192,4,7,,103173872,2913,Active,543727.0,3356.0,0.000973,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
634,625193,5,5,,103173872,2913,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
635,625194,4,7,,103173872,2913,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
636,625195,4,7,,103173872,2913,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
637,625196,5,6,,103173872,2913,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
638,625197,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
639,625198,4,7,,103173872,2913,Active,1168247.0,29412.0,0.24100000000000002,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
640,625199,4,7,,103173872,2913,Active,543734.0,24173.0,0.08,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
641,625200,4,7,,103173872,2913,Active,1168243.0,146.0,0.107,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
642,625201,4,7,,103173872,2913,Active,1351829.0,150.0,0.28300000000000003,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
643,625202,4,7,,103173872,2913,Active,613504690.0,151.0,0.038,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
644,625203,4,7,,103173872,2913,Active,20141211.0,152.0,1.275,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
645,625204,4,7,,103173872,2913,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
646,625205,4,7,,103173872,2913,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
647,625206,4,7,,103173872,2913,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
648,625207,4,7,,103173872,2913,Active,128616.0,6530.0,0.564,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
649,625208,5,5,,103173872,2913,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
650,625209,4,7,,103173872,2913,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
651,625210,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
652,625211,1,6,,103173872,2913,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
653,625212,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
654,625213,4,7,,103173872,2913,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
655,625214,1,9,,103173872,2913,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
656,625215,3,4,,103173872,2913,Active,,,1.925,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
657,625216,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
658,625217,4,7,,103173872,2913,Active,1168220.0,3357.0,0.00944,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
659,625218,4,7,,103173872,2913,Active,112816.0,3358.0,0.00244,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
660,625219,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
661,625220,4,7,,103173872,2913,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
662,625221,4,7,,103173872,2913,Active,1703010.0,3362.0,0.281,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
663,625222,4,7,,103173872,2913,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
664,625223,4,7,,103173872,2913,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
665,625224,3,4,,103173872,2913,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
666,625225,3,4,,103173872,2913,Active,,,1.167,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
667,625226,4,7,,103173872,2913,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
668,625227,4,7,,103173872,2913,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
669,625228,4,7,,103173872,2913,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
670,625229,5,5,,103173872,2913,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
671,625230,1,6,,103173872,2913,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
672,625231,4,7,,103173872,2913,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
673,625232,1,9,,103173872,2913,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
674,625233,4,7,,103173872,2913,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
675,625234,3,4,,103173872,2913,Active,,,0.43799999999999994,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
676,625235,4,7,,103173872,2913,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
677,625236,5,5,,103173872,2913,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
678,625237,4,7,,103173872,2913,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
679,625238,4,7,,103173872,2913,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
680,625239,4,7,,103173872,2913,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
681,625240,1,9,,103173872,2913,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
682,625241,4,7,,103173872,2913,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
683,625242,4,7,,103173872,2913,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
684,625243,5,5,,103173872,2913,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
685,625244,5,5,,103173872,2913,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
686,625245,5,5,,103173872,2913,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
687,625246,1,9,,103173872,2913,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
688,625247,5,5,,103173872,2913,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
689,625248,5,5,,103173872,2913,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
690,625249,5,5,,103173872,2913,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
691,625250,5,5,,103173872,2913,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
692,625251,5,5,,103173872,2913,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
693,625252,4,7,,103173872,2913,Active,118228.0,1812.0,0.158,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
694,625253,4,7,,103173872,2913,Active,118206.0,1813.0,0.16399999999999998,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
695,625254,4,7,,103173872,2913,Active,1169206.0,1814.0,0.048,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
696,625255,4,7,,103173872,2913,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
697,625256,4,7,,103173872,2913,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
698,625257,4,7,,103173872,2913,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
699,625258,4,7,,103173872,2913,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
700,625259,4,7,,103173872,2913,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
701,625260,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
702,625261,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
703,625262,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
704,625263,4,7,,103173872,2913,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
705,625264,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
706,625265,1,6,,103173872,2913,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
707,625266,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
708,625267,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
709,625268,4,2,,103173872,2913,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
710,625268,4,2,,103173872,2913,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
711,625268,4,2,,103173872,2913,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
712,625268,4,2,,103173872,2913,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
713,625269,4,7,,103173872,2913,Active,547645.0,3269.0,0.0037,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
714,625270,4,7,,103173872,2913,Active,123120.0,3274.0,0.198,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
715,625271,5,5,,103173872,2913,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
716,625272,3,4,,103173872,2913,Active,,,1.307,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
717,625273,4,6,,103173872,2913,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
718,625274,1,6,,103173872,2913,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
719,625275,3,4,,103173872,2913,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
720,625279,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
721,625280,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
722,625281,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
723,625282,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
724,625283,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
725,625284,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
726,625285,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
727,625286,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
728,625287,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
729,625288,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
730,625289,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
731,625290,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
732,625291,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
733,625292,1,3,,103173872,2913,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
734,651548,1,1,,85787813,2913,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
735,651631,4,1,,144203663,2913,Inconclusive,269849759.0,7157.0,5.308,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
736,651632,4,1,,144203663,2913,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
737,651633,4,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
738,651634,4,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
739,651635,1,3,,11110965,2913,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
740,651635,1,3,,90341656,2913,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
741,651828,1,2,,92309316,2913,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
742,652048,1,2,,144203663,2913,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
743,652051,1,1,,144203663,2913,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
744,652106,1,1,,90341656,2913,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
745,671883,1,2,,103173872,2913,Unspecified,,,,,Inhibition of hypersensitive immune responses in rat passive cutaneous anaphylaxis model at 30 mg/kg,Other,22394077.0,
746,686977,2,1,,49698345,2913,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
747,686978,1,1,,124879679,2913,Active,79154014.0,55775.0,26.6086,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
748,686978,1,1,,144203663,2913,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
749,686979,1,1,,124879679,2913,Active,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
750,686979,1,1,,144203663,2913,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
751,697464,1,4,,103173872,2913,Active,,,0.00045999999999999996,Ki,Antagonist activity at 5HT2A receptor,Confirmatory,22694093.0,
752,720516,2,1,,144203663,2913,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
753,720532,1,1,,11110965,2913,Active,420597.0,,11.2202,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
754,720532,1,1,,124879679,2913,Active,420597.0,,12.5893,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
755,720532,1,1,,144203663,2913,Active,420597.0,,8.9125,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
756,720533,1,1,,11110965,2913,Inconclusive,,,7.9433,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
757,720533,1,1,,124879679,2913,Inconclusive,,,17.7828,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
758,720533,1,1,,144203663,2913,Active,,,28.1838,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
759,720538,1,2,,90341656,2913,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
760,720552,2,1,,144203663,2913,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
761,720559,1,2,,90341656,2913,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
762,720572,1,2,,90341656,2913,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
763,720573,1,2,,90341656,2913,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
764,720634,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
765,720635,2,1,,144203663,2913,Inconclusive,,,9.4392,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
766,720637,2,1,,144203663,2913,Inconclusive,,,7.7911399999999995,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
767,720641,1,2,,92309316,2913,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
768,720674,2,2,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
769,720675,2,2,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
770,720678,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
771,720679,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
772,720680,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
773,720681,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
774,720682,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
775,720683,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
776,720684,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
777,720685,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
778,720686,2,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
779,720687,2,2,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
780,720691,4,1,,144203663,2913,Inactive,311348376.0,2908.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
781,720692,3,1,,144203663,2913,Inconclusive,311348376.0,2908.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
782,720693,3,1,,144203663,2913,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
783,720717,1,3,,92309316,2913,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
784,720719,2,1,,144203663,2913,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
785,720725,2,1,,144203663,2913,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
786,743012,3,1,,144203663,2913,Active,,,7.4978,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
787,743014,3,1,,144203663,2913,Active,,,10.5909,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
788,743015,3,1,,144203663,2913,Active,,,13.3332,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
789,743033,3,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
790,743035,2,1,,144203663,2913,Inconclusive,124375976.0,367.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
791,743036,2,1,,144203663,2913,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
792,743040,3,1,,144203663,2913,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
793,743041,3,1,,144203663,2913,Inconclusive,,,31.21,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
794,743042,3,1,,144203663,2913,Inconclusive,124375976.0,367.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
795,743053,2,1,,144203663,2913,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
796,743054,2,1,,144203663,2913,Active,124375976.0,367.0,21.9584,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
797,743063,2,1,,144203663,2913,Inconclusive,124375976.0,367.0,23.9145,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
798,743064,3,1,,144203663,2913,Active,,,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
799,743065,3,1,,144203663,2913,Active,399498506.0,24831.0,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
800,743066,3,1,,144203663,2913,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
801,743067,2,1,,144203663,2913,Inconclusive,399498506.0,24831.0,14.9601,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
802,743069,2,1,,144203663,2913,Inconclusive,348019627.0,2099.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
803,743074,2,1,,144203663,2913,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
804,743075,2,1,,144203663,2913,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
805,743077,2,1,,144203663,2913,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
806,743078,2,1,,144203663,2913,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
807,743079,3,1,,144203663,2913,Inactive,348019627.0,2099.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
808,743080,3,1,,144203663,2913,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
809,743081,3,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
810,743083,3,1,,144203663,2913,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
811,743084,3,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
812,743085,3,1,,144203663,2913,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
813,743086,3,1,,144203663,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
814,743091,2,1,,144203663,2913,Inconclusive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
815,743094,3,1,,144203663,2913,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
816,743122,2,1,,144203663,2913,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
817,743139,2,1,,144203663,2913,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
818,743140,2,1,,144203663,2913,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
819,743191,3,1,,170465127,2913,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
820,743194,3,1,,170465127,2913,Inconclusive,,,5.9553,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
821,743199,2,1,,170465127,2913,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
822,743202,4,1,,170465127,2913,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
823,743203,3,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
824,743205,1,1,,90341656,2913,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
825,743205,1,1,,90341656,2913,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
826,743206,1,1,,90341656,2913,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
827,743206,1,1,,90341656,2913,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
828,743207,1,1,,90341656,2913,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
829,743207,1,1,,90341656,2913,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
830,743209,3,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
831,743210,4,1,,170465127,2913,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
832,743211,3,1,,170465127,2913,Inconclusive,,,21.13,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
833,743212,3,1,,170465127,2913,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
834,743213,3,1,,170465127,2913,Inconclusive,,,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
835,743215,3,1,,170465127,2913,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
836,743217,3,1,,170465127,2913,Inconclusive,325495553.0,9971.0,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
837,743218,3,1,,170465127,2913,Inconclusive,,,37.5751,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
838,743219,3,1,,170465127,2913,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
839,743220,3,1,,170465127,2913,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
840,743221,3,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
841,743222,3,1,,170465127,2913,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
842,743223,3,1,,170465127,2913,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
843,743224,3,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
844,743225,3,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
845,743226,2,1,,170465127,2913,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
846,743227,2,1,,170465127,2913,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
847,743228,3,1,,170465127,2913,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
848,743239,2,1,,170465127,2913,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
849,743240,2,1,,170465127,2913,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
850,743241,2,1,,170465127,2913,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
851,743242,2,1,,170465127,2913,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
852,743244,1,1,,90341656,2913,Inconclusive,,,0.7943,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
853,743244,1,1,,144203663,2913,Inconclusive,,,28.1838,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
854,743344,1,1,,174007288,2913,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
855,743345,1,1,,174007288,2913,Inactive,,,8.4071,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
856,743346,1,1,,174007288,2913,Inactive,,,2.983,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
857,743347,1,1,,174007288,2913,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
858,939162,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020514,Other,,
859,939163,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020514,Other,,
860,939164,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020514,Other,,
861,939165,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020514,Other,,
862,939166,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020514,Other,,
863,939167,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020514,Other,,
864,939168,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020514,Other,,
865,939169,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020514,Other,,
866,939170,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020514,Other,,
867,939171,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020514,Other,,
868,939172,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020514,Other,,
869,939173,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020514,Other,,
870,939174,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020514,Other,,
871,945356,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020514,Other,,
872,945357,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020514,Other,,
873,945358,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020514,Other,,
874,945359,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020514,Other,,
875,945360,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020514,Other,,
876,945361,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020514,Other,,
877,945362,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020514,Other,,
878,945363,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020514,Other,,
879,945364,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020514,Other,,
880,945365,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020514,Other,,
881,945366,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020514,Other,,
882,945367,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020514,Other,,
883,945368,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020514,Other,,
884,951778,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020514,Other,,
885,951779,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020514,Other,,
886,951780,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020514,Other,,
887,951781,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020514,Other,,
888,952958,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020514,Other,,
889,952959,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020514,Other,,
890,952960,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020514,Other,,
891,952961,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020514,Other,,
892,952962,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020514,Other,,
893,952963,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020514,Other,,
894,952964,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020514,Other,,
895,952965,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020514,Other,,
896,952966,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020514,Other,,
897,952967,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020514,Other,,
898,972051,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020514,Other,,
899,972052,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020514,Other,,
900,972683,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020514,Other,,
901,972684,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020514,Other,,
902,972685,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020514,Other,,
903,972686,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020514,Other,,
904,972687,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020514,Other,,
905,972688,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020514,Other,,
906,972689,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020514,Other,,
907,972690,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020514,Other,,
908,972691,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020514,Other,,
909,972692,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020514,Other,,
910,972693,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020514,Other,,
911,972694,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020514,Other,,
912,996078,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
913,996079,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
914,996080,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R020514,Other,,
915,996081,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020514",Other,,
916,996082,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R020514",Other,,
917,996083,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R020514",Other,,
918,996084,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R020514",Other,,
919,996085,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R020514",Other,,
920,996086,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R020514",Other,,
921,996087,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020514",Other,,
922,996088,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020514",Other,,
923,996673,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R020514",Other,,
924,996674,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R020514",Other,,
925,996675,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
926,996676,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R020514",Other,,
927,996677,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R020514",Other,,
928,996678,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R020514",Other,,
929,996679,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R020514",Other,,
930,996680,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R020514",Other,,
931,996681,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R020514,Other,,
932,996682,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R020514",Other,,
933,996683,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R020514,Other,,
934,996684,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R020514",Other,,
935,996685,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R020514",Other,,
936,996686,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R020514",Other,,
937,996687,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R020514",Other,,
938,998548,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R020514",Other,,
939,998549,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R020514",Other,,
940,998550,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R020514",Other,,
941,998551,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R020514",Other,,
942,998552,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R020514",Other,,
943,998553,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
944,998554,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R020514",Other,,
945,998555,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R020514",Other,,
946,998556,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R020514,Other,,
947,998557,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
948,998558,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
949,998559,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
950,998560,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R020514",Other,,
951,998561,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R020514",Other,,
952,998562,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020514",Other,,
953,998563,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R020514",Other,,
954,998564,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R020514",Other,,
955,998565,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R020514",Other,,
956,998566,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R020514",Other,,
957,998567,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R020514",Other,,
958,999150,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R020514",Other,,
959,999151,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R020514",Other,,
960,999152,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R020514",Other,,
961,999153,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R020514",Other,,
962,999154,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R020514",Other,,
963,999155,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R020514",Other,,
964,999156,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R020514",Other,,
965,999157,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R020514",Other,,
966,999158,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R020514",Other,,
967,999159,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R020514,Other,,
968,999160,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R020514,Other,,
969,999161,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R020514",Other,,
970,999162,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020514",Other,,
971,999163,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R020514",Other,,
972,999164,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R020514",Other,,
973,999165,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
974,999166,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
975,999167,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R020514",Other,,
976,999168,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R020514",Other,,
977,999169,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R020514",Other,,
978,1001029,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R020514",Other,,
979,1001030,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
980,1001031,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R020514",Other,,
981,1001032,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R020514",Other,,
982,1001033,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R020514,Other,,
983,1001034,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R020514",Other,,
984,1001035,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
985,1001036,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R020514",Other,,
986,1001037,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R020514",Other,,
987,1001038,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R020514",Other,,
988,1001039,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R020514,Other,,
989,1001040,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
990,1001041,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R020514",Other,,
991,1001042,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
992,1001043,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R020514",Other,,
993,1001044,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R020514",Other,,
994,1001625,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R020514",Other,,
995,1001626,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R020514",Other,,
996,1001627,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
997,1001628,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R020514",Other,,
998,1001629,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R020514",Other,,
999,1001630,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R020514",Other,,
1000,1001631,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R020514",Other,,
1001,1001632,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
1002,1001633,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R020514",Other,,
1003,1001634,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R020514",Other,,
1004,1001635,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R020514",Other,,
1005,1001636,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R020514",Other,,
1006,1001637,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020514",Other,,
1007,1001638,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R020514",Other,,
1008,1001639,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R020514",Other,,
1009,1001640,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R020514",Other,,
1010,1001641,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R020514,Other,,
1011,1001642,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R020514",Other,,
1012,1001643,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R020514",Other,,
1013,1001644,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R020514",Other,,
1014,1001645,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
1015,1001646,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R020514",Other,,
1016,1001647,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
1017,1001648,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R020514",Other,,
1018,1003518,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R020514",Other,,
1019,1003519,1,3,,103173872,2913,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R020514,Other,,
1020,1003520,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R020514",Other,,
1021,1003521,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R020514",Other,,
1022,1003522,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R020514",Other,,
1023,1003523,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R020514",Other,,
1024,1003524,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R020514",Other,,
1025,1003525,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R020514",Other,,
1026,1003526,1,3,,103173872,2913,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R020514",Other,,
1027,1079931,1,1,,103173872,2913,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1028,1079932,1,1,,103173872,2913,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1029,1079933,1,1,,103173872,2913,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1030,1079934,1,1,,103173872,2913,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1031,1079935,1,1,,103173872,2913,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1032,1079936,1,1,,103173872,2913,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1033,1079937,1,1,,103173872,2913,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1034,1079938,1,1,,103173872,2913,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1035,1079939,1,1,,103173872,2913,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1036,1079940,1,1,,103173872,2913,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1037,1079941,1,1,,103173872,2913,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1038,1079942,1,1,,103173872,2913,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1039,1079943,1,1,,103173872,2913,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1040,1079944,1,1,,103173872,2913,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1041,1079945,1,1,,103173872,2913,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1042,1079946,1,1,,103173872,2913,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1043,1079947,1,1,,103173872,2913,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1044,1079948,1,1,,103173872,2913,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1045,1079949,1,1,,103173872,2913,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1046,1117298,1,2,,170465127,2913,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1047,1117301,1,2,,170465127,2913,Inactive,,,12.5893,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
1048,1117302,1,2,,170465127,2913,Inactive,,,12.5893,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
1049,1117303,1,2,,170465127,2913,Inactive,,,14.13,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
1050,1117304,1,2,,170465127,2913,Active,,,11.2202,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1051,1117305,1,2,,170465127,2913,Active,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1052,1117308,1,1,,170465127,2913,Active,,,17.2141,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, ratio channel",Confirmatory,,
1053,1117309,1,1,,170465127,2913,Inactive,,,19.3145,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, blue channel",Confirmatory,,
1054,1117310,1,1,,170465127,2913,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1055,1117311,1,1,,170465127,2913,Inactive,,,12.5893,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
1056,1117312,1,1,,170465127,2913,Active,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1057,1117314,1,1,,170465127,2913,Inactive,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1058,1117315,1,1,,170465127,2913,Inactive,,,12.5893,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
1059,1117316,1,1,,170465127,2913,Inactive,,,15.342,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, green channel",Confirmatory,,
1060,1117318,1,1,,170465127,2913,Active,,,14.1254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
1061,1117322,1,1,,170465127,2913,Inactive,,,11.2853,IC50,RKO viability from Cell TiterGlo-IC50,Confirmatory,,
1062,1117323,1,1,,170465127,2913,Inactive,,,10.7827,IC50,SNU-C1 viability from Cell TiterGlo-IC50,Confirmatory,,
1063,1117326,1,1,,170465127,2913,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1064,1117329,1,1,,170465127,2913,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1065,1117330,1,1,,170465127,2913,Inactive,,,20.0,IC50,HT-29 viability from Cell TiterGlo-IC50,Confirmatory,,
1066,1117332,1,1,,170465127,2913,Inactive,,,20.0,IC50,HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
1067,1117334,1,1,,170465127,2913,Inactive,,,20.0,IC50,Colo320 viability from Cell TiterGlo-IC50,Confirmatory,,
1068,1117336,1,1,,170465127,2913,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1069,1117338,1,1,,170465127,2913,Inactive,,,5.9167,IC50,SW480 viability from Cell TiterGlo-IC50,Confirmatory,,
1070,1117339,1,1,,170465127,2913,Inactive,,,20.0,IC50,GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
1071,1117340,1,1,,170465127,2913,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1072,1117341,1,1,,170465127,2913,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1073,1117342,1,1,,170465127,2913,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1074,1117343,1,1,,170465127,2913,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1075,1117346,1,1,,170465127,2913,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1076,1117352,1,1,,170465127,2913,Inactive,,,20.0,IC50,DLD-1 viability from Cell TiterGlo-IC50,Confirmatory,,
1077,1132675,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in guinea pig ileum strips assessed as inhibition of serotonin-induced anaphylaxis,Other,660595.0,
1078,1132676,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in guinea pig ileum strips assessed as inhibition of bradykinin-induced anaphylaxis,Other,660595.0,
1079,1132677,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2-induced anaphylaxis,Other,660595.0,
1080,1132678,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis,Other,660595.0,
1081,1132679,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in guinea pig lung tissue assessed as inhibition of SRS-A production,Other,660595.0,
1082,1132680,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2-induced anaphylaxis at 25 ug/ml,Other,660595.0,
1083,1132681,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis at 25 ug/ml,Other,660595.0,
1084,1132682,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis at 100 ug/ml,Other,660595.0,
1085,1132683,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in guinea pig lung tissue assessed as inhibition of SRS-A production at 1 ug/ml,Other,660595.0,
1086,1132684,1,1,,103173872,2913,Unspecified,,,,,"Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction at 10 mg/kg, iv after 30 mins by Evans blue staining",Other,660595.0,
1087,1132686,1,1,,103173872,2913,Unspecified,,,,,"Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction at 3 mg/kg, iv after 30 mins by Evans blue staining",Other,660595.0,
1088,1132687,1,1,,103173872,2913,Unspecified,,,,,"Toxicity in adrenalectomized Sprague-Dawley rat at 10 mg/kg, iv",Other,660595.0,
1089,1132688,1,2,,103173872,2913,Unspecified,,,,,Antiallergic activity in in guinea pig ileum strips assessed as inhibition of histamine-induced anaphylaxis,Other,660595.0,
1090,1135534,1,1,,103173872,2913,Unspecified,,,,,Peripheral anticholinergic activity in po dosed Carworth CF1 mouse assessed as dose required to produce pupil dilation to 1.5 micrometer units in 50% mouse after 2 hrs,Other,19627.0,
1091,1135536,1,1,,103173872,2913,Unspecified,,,,,"Central anticholinergic activity against physostigmine-induced lethality in Carworth CF1 mouse assessed as animal death at 10 mg/kg, po treated 5 hrs before 1.6 mg/kg, sc physostigmine treatment and 2 mg/kg, ip atropine methyl nitrate treated 0.5 hrs before induction (Rvb = 0%)",Other,19627.0,
1092,1148107,1,1,,103173872,2913,Unspecified,,,,,Antiserotonin activity against po dosed Sprague-Dawley rat assessed as inhibition of serotonin-induced edema of right hind paw compound administered 1 hr prior to serotonin challenge,Other,592336.0,
1093,1148108,1,1,,103173872,2913,Unspecified,,,,,Antihistaminic activity against ip dosed Duncan-Harley guinea pig assessed as inhibition of histamine aerosol-induced bronchoconstriction compound administered 30 mins prior to histamine challenge,Other,592336.0,
1094,1148109,1,1,,103173872,2913,Unspecified,,,,,Anticholinergic activity in po dosed CF-1 mouse assessed as dose required to increase pupil diameter to 1.5 micrometer after 1 hr,Other,592336.0,
1095,1148116,1,1,,103173872,2913,Unspecified,,,,,"Orexigenic activity in cat assessed as food consumption at 0. 0312 mg/kg, po (Rvb = 133 +/- 31 g)",Other,592336.0,
1096,1148117,1,1,,103173872,2913,Unspecified,,,,,"Orexigenic activity in cat assessed as food consumption at 0. 25 mg/kg, po (Rvb = 179 +/- 31 g)",Other,592336.0,
1097,1159387,1,2,,103173872,2913,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
1098,1159509,1,1,,170465127,2913,Inconclusive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1099,1159515,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1100,1159516,1,1,,170465127,2913,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1101,1159517,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1102,1159518,1,1,,170465127,2913,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1103,1159519,1,1,,170465127,2913,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1104,1159520,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1105,1159521,1,1,,170465127,2913,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1106,1159523,1,1,,170465127,2913,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1107,1159524,1,1,,124879679,2913,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1108,1159525,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1109,1159526,1,1,,170465127,2913,Inconclusive,119627033.0,3725.0,4.7716,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1110,1159527,1,1,,170465127,2913,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1111,1159528,1,1,,170465127,2913,Active,119627033.0,3725.0,7.2777,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1112,1159529,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1113,1159531,1,1,,170465127,2913,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1114,1159551,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1115,1159552,1,1,,170465127,2913,Inconclusive,325495463.0,5914.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1116,1159553,2,1,,170465127,2913,Inactive,325495463.0,5914.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1117,1159555,1,1,,170465127,2913,Active,325495463.0,5914.0,12.3481,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1118,1159580,2,1,,268735209,2913,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1119,1159580,2,1,,273002746,2913,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1120,1159607,2,1,,312309693,2913,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1121,1159614,1,2,,170465127,2913,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1122,1224824,1,1,,174007288,2913,Inactive,,,0.1177,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1123,1224825,1,1,,174007288,2913,Inactive,,,4.1763,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1124,1224834,3,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1125,1224835,1,1,,170465127,2913,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1126,1224836,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1127,1224837,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1128,1224838,1,1,,170465127,2913,Inactive,66775687.0,9970.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1129,1224839,1,1,,170465127,2913,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1130,1224840,3,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1131,1224841,3,1,,170465127,2913,Inactive,325495545.0,2101.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1132,1224842,3,1,,170465127,2913,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1133,1224843,1,1,,170465127,2913,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1134,1224844,1,1,,170465127,2913,Inconclusive,,,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1135,1224845,1,1,,170465127,2913,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1136,1224846,1,1,,170465127,2913,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1137,1224847,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1138,1224848,3,1,,170465127,2913,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1139,1224849,3,1,,170465127,2913,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1140,1224857,2,1,,170465127,2913,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1141,1224857,2,1,,174007288,2913,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1142,1224859,2,1,,90341656,2913,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1143,1224859,2,1,,170465127,2913,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1144,1224859,2,1,,174007288,2913,Inactive,,,3.3173,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1145,1224863,1,1,,176484559,2913,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1146,1224863,1,1,,316919497,2913,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1147,1224867,1,1,,170465127,2913,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1148,1224868,1,1,,170465127,2913,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1149,1224869,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1150,1224870,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1151,1224871,1,1,,170465127,2913,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1152,1224872,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1153,1224873,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1154,1224874,1,1,,170465127,2913,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1155,1224875,1,1,,170465127,2913,Inactive,,,0.2391,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1156,1224876,1,1,,170465127,2913,Inconclusive,,,21.3138,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1157,1224877,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1158,1224878,1,1,,170465127,2913,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1159,1224879,1,1,,170465127,2913,Active,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1160,1224880,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1161,1224881,1,1,,170465127,2913,Inactive,,,0.2391,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1162,1224882,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1163,1224883,1,1,,170465127,2913,Active,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1164,1224884,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1165,1224885,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1166,1224886,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1167,1224887,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1168,1224888,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1169,1224889,1,1,,170465127,2913,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1170,1224890,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1171,1224892,1,1,,170465127,2913,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1172,1224893,1,1,,170465127,2913,Inconclusive,66775687.0,9970.0,19.5704,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1173,1224894,1,1,,170465127,2913,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1174,1224895,1,1,,170465127,2913,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1175,1224896,1,1,,170465127,2913,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1176,1224905,2,1,,92309316,2913,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1177,1224905,2,1,,92309316,2913,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1178,1251558,1,1,,103173872,2913,Active,25091217.0,80854.0,20.0,IC50,Inhibition of SET7 (unknown origin),Confirmatory,26390175.0,
1179,1257280,1,1,,103173872,2913,Unspecified,5921694.0,100135490.0,42.22,IC50,Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in guinea pig ventricular myocytes,Confirmatory,,
1180,1257281,1,1,,103173872,2913,Unspecified,5921694.0,100135490.0,7.75,IC50,Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in guinea pig ventricular myocytes,Confirmatory,,
1181,1259241,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1182,1259242,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1183,1259243,1,1,,170465127,2913,Active,124375976.0,367.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1184,1259244,1,1,,170465127,2913,Inconclusive,348019627.0,2099.0,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1185,1259247,1,1,,170465127,2913,Inconclusive,124375976.0,367.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1186,1259248,1,1,,170465127,2913,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1187,1259252,1,1,,174007288,2913,Active,169655958.0,,9.3495,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1188,1259253,1,1,,174007288,2913,Active,169655958.0,,16.6261,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1189,1259255,1,1,,174007288,2913,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1190,1259256,1,1,,174007288,2913,Inconclusive,169655958.0,,18.6548,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1191,1259325,1,2,,336955419,2913,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1192,1259344,1,1,,144203663,2913,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1193,1259355,1,1,,26751603,2913,Inconclusive,,,0.3981,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1194,1259356,1,1,,144203663,2913,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1195,1259364,1,1,,170465127,2913,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1196,1259365,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1197,1259366,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1198,1259367,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1199,1259368,1,1,,170465127,2913,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1200,1259369,1,1,,170465127,2913,Active,109731339.0,2737.0,0.3349,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1201,1259377,1,1,,170465127,2913,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1202,1259378,1,1,,170465127,2913,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1203,1259379,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1204,1259380,1,1,,170465127,2913,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1205,1259381,1,1,,170465127,2913,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1206,1259382,1,1,,170465127,2913,Active,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1207,1259383,1,1,,170465127,2913,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1208,1259384,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1209,1259385,1,1,,170465127,2913,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1210,1259386,1,1,,170465127,2913,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1211,1259387,1,1,,170465127,2913,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1212,1259388,1,1,,170465127,2913,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1213,1259390,1,1,,170465127,2913,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1214,1259391,1,1,,170465127,2913,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1215,1259392,1,1,,170465127,2913,Active,109731339.0,2737.0,0.668242,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1216,1259393,1,1,,170465127,2913,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1217,1259394,1,1,,170465127,2913,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1218,1259395,1,1,,170465127,2913,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1219,1259396,1,1,,170465127,2913,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1220,1259400,1,1,,170465127,2913,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1221,1259401,1,1,,170465127,2913,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1222,1259402,1,1,,170465127,2913,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1223,1259403,1,1,,170465127,2913,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1224,1259404,1,1,,170465127,2913,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1225,1259407,1,1,,363903182,2913,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1226,1259408,1,1,,363895416,2913,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
1227,1259416,1,2,,340079777,2913,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1228,1259416,1,2,,340079778,2913,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1229,1259416,1,2,,375177953,2913,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1230,1259420,1,1,,375272324,2913,Inactive,56786138.0,3458.0,,AC50_uM,Toxoplasma gondii at dose in the absence of IFN-y,Confirmatory,,
1231,1259421,1,1,,340079777,2913,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1232,1259421,1,1,,340079778,2913,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1233,1259421,1,1,,375177953,2913,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1234,1259423,1,2,,354783036,2913,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1235,1259423,1,2,,354804057,2913,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1236,1259423,1,2,,354919485,2913,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1237,1259423,1,2,,355028149,2913,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
